Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT03042143 |
| Other study ID # |
16154DMcA-AS |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
Phase 1/Phase 2
|
| First received |
|
| Last updated |
|
| Start date |
January 7, 2019 |
| Est. completion date |
June 2025 |
Study information
| Verified date |
May 2023 |
| Source |
Belfast Health and Social Care Trust |
| Contact |
Danny F McAuley, MD |
| Phone |
02890976385 |
| Email |
d.f.mcauley[@]qub.ac.uk |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Acute Respiratory Distress Syndrome (ARDS) causes the lungs to fail due to the collection of
fluid in the lungs (pulmonary oedema). ARDS is common in severely ill patients in Intensive
Care Units and is associated with a high mortality and a high morbidity in those who survive.
ARDS occurs in approximately 20% case of COVID-19 and respiratory failure is the leading
cause of mortality. There is a large economic burden with direct healthcare costs, but also
indirectly due to the impact on the carer and patient through the patients inability to
return to full time employment. There is little evidence for effective drug (pharmacological)
treatment for ARDS. There is increasing information that mesenchymal stem cells (MSCs) might
be important in treating ARDS. REALIST will investigate if a single infusion of MSCs will
help in the treatment of ARDS. The first step will be to first of all determine what dose of
MSCs is safe and then divide patients suffering from ARDS into two groups, one of which will
get MSCs and the other a harmless dummy (or placebo) infusion, who will then be followed up
to determine if lung function improves. If effective this may lead to further research to
determine if MSCs are effective in patients with ARDS.
Description:
The role of MSCs as a novel treatment in ARDS. Mesenchymal Stem Cells (MSCs) are a
mononuclear cell population that have the potential to differentiate into multiple lineages,
and bone, cartilage and adipocyte cells in particular. Cell-based therapies have been termed
the "next pillar of Medicine". MSCs constitute an innovative approach with substantial
therapeutic promise for ARDS. MSCs possess several favorable biological characteristics,
including convenient isolation, ease of expansion in culture while maintaining genetic
stability, minimal immunogenicity and feasibility for allogenic transplantation.
MSCs reduce inflammation and enhance bacterial clearance during rodent and murine bacterial
pneumonia, and augment repair of the animal and human lung. Large animal studies have also
replicated these beneficial effects. Bone marrow derived (BM) hMSCs decreased acute lung
injury (ALI), without producing organ toxicity, in endotoxin injured pigs. Two randomised
small phase 1 studies of plastic adherent MSCs in patients with ARDS have taken place. In
Japan, investigators used adipose-derived plastic adherent cells in a small cohort (n=12) of
patients with ARDS randomized 1:1 to MSCs or placebo: showing that the cells were safe and
well-tolerated in this patient group, and were associated with reduced plasma levels of the
alveolar epithelial cell injury marker SP-D. In the US Matthay has completed the phase 1
START trial, using a dose escalation study of plastic adherent bone marrow derived MSCs, in
patients with moderate to severe ARDS. START showed that marrow derived MSCs at similar doses
to those proposed in this study are safe and well-tolerated, (n=9), with a trend to reduced
lung injury in the group treated with the highest (10x10^6cells/kg) compared with the lower
doses, 1-5x10^6cells/kg.
Current (20 March 2020) data on novel coronavirus disease (COVID-19) suggests that it causes
a mortality rate of ~3.4%, compared with <0.1% with seasonal influenza. ARDS occurs in
approximatel 20% cases of COVID-19 and respiratory failure is the leading cause of mortality.
In a restropective multi-centre study of 150 confirmed cases in Wuhan, China, ARDS occured in
significantly greater proportion of non-survivors 81% (55/68 patients) compared with only 9%
survivors (7/82 patients); p<0.01. In another study of 193 confirmed COVID-19 cases, ARDS was
observed at a significantly higher rate in non-survivors 93% (50/54 patients) compared with
survivors, 7% (9/137) patients; p<0.0001.
During the current COVID-19 pandemic, MSCs have been administered in a pilot study of seven
patients with COVID-19 pneumonia. A single infusion of 1 x 10^6 MSCs were administered
intravenously when their condition was considered to be deteriorating despite other
treatments, however only 1 of the 7 patients required critical care and mechanical
ventilation. 4 patients were described as severe with compromise of respiratory function.
Patients underwent follow up for 14 days and no infusional toxicity or adverse events were
reported.
Trial design:
The phase 1 trial is an open label dose escalation pilot study in which cohorts of subjects
with moderate to severe ARDS will receive increasing doses of a single infusion of Realist
Orbcel-C in a 3+3 design. We initially plan 3 cohorts with 3 subjects/cohort. Planned doses
for the 3 cohorts pending absence of safety concerns are 100 x 10^6 cells, 200 x 10^6 cells
and 400 x 10^6 cells.
In the completed Phase 1 REALIST trial, infusion of 400 million cells was achieved without
any dose limiting toxicity at day 7 and has been approved by the DMEC as the intervention for
this study.
The phase 2 trial is a randomized, double-blind, allocation concealed placebo-controlled
study using the 400x10^6 cell dose of Realist Orbcel-C in patients with moderate to severe
ARDS due to either COVID-19 or other causes of ARDS.
Primary objective:
To assess the safety of a single intravenous infusion of REALIST ORBCEL-C cells in patients
with ARDS due to COVID-19.
Secondary objectives:
In patients with moderate to severe ARDS to determine the effect of a single intravenous
infusion of REALIST ORBCEL-C cells on:
1. Physiological indices of respiratory dysfunction reflecting severity of ARDS, as
measured by oxygenation index (OI), respiratory compliance, and P/F ratio.
2. Sequential organ failure assessment (SOFA) score.
3. Extubation and reintubation
4. Ventilation free days at day 28
5. Duration of ventilation
6. Length of ICU and hospital stay
7. 28-day and 90-day mortality
Population:
Patients will be prospectively screened daily. All patients with moderate to severe ARDS will
be entered into a screening log. If possible during the phase 2 trial, all patients with
moderate to severe ARDS due to COVID-19 or other causes of ARDS will be entered into a
screening log. If the patient is not recruited the reason will be recorded. A fully
anonymised minimal dataset will be recorded on these patients (age, gender, APACHE II score,
worst P/F ratio at time of assessment, reasons for non-enrolment and vital status). APACHE II
score and vital status will be collected using anonymised linkage to the ICNARC database
through a defined CMP number (or equivalent). This will allow comparison to identify that the
study population is representative of the overall cohort of patients. This information is
required to establish an unbiased study population and to ensure the study can be reported in
keeping with CONSORT guidelines (www.consort-statement.org).
Patient consent:
Informed consent procedure:
The study will be conducted in accordance with the ethical principles that have their origin
in the Declaration of Helsinki. The chief investigator (CI) (or designee) is responsible for
ensuring that informed consent for trial participation is given by each patient or a legal
representative. An appropriately trained doctor or nurse may take consent. The person taking
informed consent must be GCP trained, suitably qualified and experienced and have been
delegated this duty on the delegation log. Appropriate signatures and dates must be obtained
on the informed consent documentation prior to collection of trial data and administration of
the trial drug. If no consent is given a patient cannot be randomised into the trial. The
incapacitating nature of the condition precludes obtaining prospective informed consent from
participants. In this situation informed consent will be sought from a Personal Legal
Representative or Professional Legal representative.
Personal legal representative consent:
Informed consent will be sought from the patient's personal legal representative (Per LR) who
may be a relative, partner or close friend. The Per LR will be informed about the trial by
the responsible clinician or a member of the research team and provided with a copy of the
covering statement for the Per LR with an attached participant information sheet (PIS) and
asked to give an opinion as to whether the patient would object to taking part in such
medical research. If the Per LR decides that the patient would have no objection to
participating in the trial the Per LR will be asked to sign the Per LR consent form which
will then be countersigned by the person taking consent. The original will be retained in the
trial site file and a copy given to the Per LR and another copy placed in the patients'
medical records.
During the COVID-19 pandemic, there are likely to be visiting restrictions in place due to
infection control measures and therefore it may not be possible to obtain consent from the
PerLR at the clinical site. If the PerLR is not available at the site, the research may
contact the PerLR by telephone and seek verbal agreement. The verbal agreement will be
recorded in the PerLR Telephone Agreement Form.
Professional legal representative consent:
As the patient is unable to give informed consent and no Per LR is available, a doctor who is
not connected with the conduct of the trial may act as a professional legal representative
(Prof LR). The doctor will be informed about the trial by the responsible clinician or a
member of the research team and given a copy of the PIS. If the doctor decides that the
patient is suitable for entry into the trial that doctor will be asked to sign the
professional legal representative consent form. The original will be retained in the trial
site file and a copy given to the Prof LR and another copy placed in the patients' medical
records.
Retrospective patient consent:
Patients will be informed of their participation in the trial by the responsible clinician or
a member of the research team once the patient regain capacity to understand the details of
the trial. The responsible clinician or a member of the research team will discuss the study
with the patient and the patient will be given a copy of the PIS to keep. The patient will be
asked for consent to participate in the trial and to sign the consent to continue form which
will then be countersigned by the person taking consent. The original will be retained in the
trial site file and a copy given to the patient and another copy placed in the patients'
medical records. Where consent to continue is not obtained, consent from the legal
representative will remain valid. If the patient refuses consent, permission to use data
collected to that point and to access medical records for trial data will be requested from
the patient.
Withdrawal of consent:
Patients may withdraw or be withdrawn (by Per LR or Prof LR) from the trial at any time
without prejudice.
In the event of a request to withdraw from the study, the researcher will determine which
elements of the trial are to be withdrawn from the following possibilities and this will be
documented:
- Orbcel-C administration if ongoing
- On-going data collection during hospital admission
- Confirmation of vital status
- On-going data collection following hospital discharge In the event that the request is
to withdraw from all elements of the study, only anonymised data recorded up to the
point of withdrawal will be included in the study analysis.
Consent will also be requested to use the samples collected to that point.
Investigational medicinal product
The Investigational Medicinal Products are:
1. Allogeneic donor CD362 enriched human umbilical cord-derived mesenchymal stromal cells
(REALIST ORBCEL-C) supplied as a sterile, single-use cryopreserved cell suspension
containing a fixed cell dose of either 100 x 10^6, 200 x 10^6 or 400 x 10^6 cells in
10mL, 20mL or 40mL volumes, respectively to be further diluted in Plasma-Lyte 148 to a
total volume of 200mls for the purposes of administration.
2. Plasma-Lyte 148 Solution for Infusion (200mls) as the placebo control solution.
Storage, thawing and reconstitution of Orbcel-C cells:
Trial guidelines will provide detailed information regarding the protocol for storage,
thawing and reconstitution, and administration of the cell product Orbcel-C and placebo.
Drug storage:
The study drug will be commenced as soon as possible following reconstitution and within 6
hours.
Study drug termination criteria:
Study drug will be continued until one of the following is met:
1. Study drug related adverse event
2. Death or discontinuation of active treatment
3. Request from Per LR or Pro LR to withdraw the patient from the study
4. Decision by the attending clinician on safety grounds.
Study drug compliance:
Any omission of the study drug will be recorded in the CRF to monitor compliance.
Study drug accountability:
The site clinical trials pharmacist and cell therapy facility staff will maintain full
accountability for the study drug received, prepared and dispensed to patients in ICU.
Records will be kept allowing traceability between the cell donor and the IMP recipient. Drug
administration will be recorded on the patient's prescription chart.
Study drug return and destruction:
Any partially used study drug should be disposed of/destroyed at the site in accordance with
Trial guidelines and local biological waste management policies.
Unused product should disposed of/destroyed under the supervision of the site clinical trials
pharmacist. Records of return and destruction will be maintained.
Data Quality:
The NICTU will provide training to site staff on trial processes and procedures including CRF
completion and data collection. Within the NICTU the clinical data management process is
governed by SOPs to ensure standardisation and adherence to International Conference on
Harmonisation Good Clinical Practice (ICH GCP) guidelines and regulatory requirements. Data
is to be entered onto the electronic database as per the CRF entry timelines. On-site
monitoring visits during the trial will check: (i) the accuracy of the data entered into the
CRF, (ii) entries against source documents alongside adherence to the protocol, (iii) trial
specific procedures and (iv) Good Clinical Practice (GCP). This monitoring will be carried
out as per the trial specific Monitoring Plan. Changes to data will be recorded and fully
auditable. Data errors will be documented and corrective actions implemented. Data validation
will be implemented and discrepancy reports will be generated following data entry to
identify data that may be out of range or inconsistent, or protocol deviations, based on data
validation checks programmed into the clinical trial database. For routinely collected
clinical data the NHS record will be the source document and for study specific measurements
the CRF will be the source document.
Data management:
The PI (or designee) will collect all data and record this in the CRF. Each participant will
be allocated a unique participant study number at trial entry, and this, and initials, will
be used to identify him or her on the CRF for the duration of the trial. Data will be
collected from the time of trial entry until hospital discharge. Trial data will be entered
onto a CRF and processed electronically as per NICTU SOPs and the study specific Data
Management Plan (DMP). Submitted data will be reviewed for completeness and entered onto a
secure, backed-up custom database. Due care will be taken to ensure data safety and
integrity, and compliance with GDPR and the Data Protection Act 2018. Data queries will be
raised electronically. The designated site staff will be required to respond to these queries
within 2 weeks and send them back to the CTU after the queries have been reviewed and signed
by the CI/delegated staff member. Any amended information will then be entered in the study
database. A copy of the signed data query form should be retained with the CRF at the
investigator site.
If the participant is transferred to another hospital the PI or designated member of the site
study team will liaise with the receiving hospital to ensure complete data capture as per CRF
instruction. If this is not possible, the primary outcome must be collected as a minimum.
CRFs are to be submitted to the CTU as per the CRF submission schedule. Data censorship for
each trial will occur 90 days post randomisation.
Analysis Population The primary analysis will be conducted on all outcome data obtained from
all participants regardless of protocol adherence, i.e. intention to treat analysis.
It is possible that some enrolled subjects may not be treated with study drug. Therefore a
secondary analysis of the all-treated population analysis will be undertaken.
For the Phase 1 trial no formal statistical analysis will be performed on safety data. The
primary analysis will be descriptive and will focus on adverse events. The number of pre
specified cell infusion associated events will also be reported. Descriptive analysis of
pulmonary and non-pulmonary organ function will also be undertaken. We plan to publish the
data from the phase 1 study.
In the completed Phase 1 REALIST trial, infusion of 400 million cells was achieved without
any dose limiting toxicity at day 7 and has been approved by the DMEC as the intervention
dose for this study.
For the Phase 2 trial, adverse events will be reported as for the Phase 1 study. For
continuously distributed outcomes, differences between groups will be tested using
independent samples t-tests and analysis of covariance with transformations of variables to
normality if appropriate, or non-parametric equivalents. Chi-square tests (or Fisher's Exact
tests) will be used for categorical variables. A p value of 0.05 will be considered as
significant.
Correlations between changes in the biological markers measured and physiological and
clinical outcomes will be assessed by appropriate graphical and statistical methods including
Pearson's (or Spearman's) correlation coefficient.
A final analysis and report of the Phase 1 study is planned following the last patient's 90
day follow up. A final analysis and report of the phase 2 study is planned following the last
patient's 90 day follow up. The 2 year follow up data will be published thereafter and will
be an important long term outcome. A detailed statistical analysis plan will be written and
approved by the independent DMEC prior to any analysis.
All the power calculations and methodology for data analysis have been confirmed by the trial
statistician from the Northern Ireland Clinical Trials Unit (NICTU).
Missing data:
Every effort will be made to minimise missing baseline and outcome data in this trial. The
level and pattern of the missing data in the baseline variables and outcomes will be
established by forming appropriate tables and the likely causes of any missing data will be
investigated. This information will be used to determine whether the level and type of
missing data has the potential to introduce bias into the analysis results for the proposed
statistical methods, or substantially reduce the precision of estimates related to treatment
effects. If necessary, these issues will be dealt with using multiple imputation or Bayesian
methods for missing data as appropriate.
Sample size:
The phase 1 trial will recruit up to 18 participants. The sample size for the phase 2 REALIST
trial is 60 patients with ARDS due to COVID-19 and 60 patients with ARDS not due to COVID-19
(30 in each of the ORBCEL-C and placebo groups). Due to the clinical differences in patients
with ARDS due to COVID-19 and other causes of ARDS, patients with ARDS due to COVID-19 and
other causes of ARDS will be recruited as separate cohorts. This will also facilitate timely
reporting of the results from each cohort.
Although the primary focus of the phase 2 trial is safety, there is, however, power to detect
a difference in physiological outcomes.
The primary efficacy outcome measure will be the difference in oxygenation index (OI) between
the ORBCEL-C and placebo treated groups at day 7. Based on our data from a recently completed
clinical trial in ARDS, the mean (standard deviation; SD) OI at day 7 in patients with ARDS
is 62(51)cmH2O/kPa [4]. To allow 1:1 recruitment (ORBCEL-C vs placebo) a sample size of 56
subjects will have 80% power at a two-tailed significance level of 0.05 using a two-sample
t-test to detect a clinically significant difference of 39 cmH2O/kPa in OI between groups. In
a previous phase 2 study of similar size, we have found that an intervention can demonstrate
a change in OI of a similar magnitude confirming a treatment effect of this size can be
achieved [4].
Although we anticipate few withdrawals or loss to follow-up we have allowed for this in the
sample size calculation. In previous UK multicentre studies in the critically ill <3%
withdrew consent or were lost to follow-up [4, 65]. Therefore, a conservative drop-out rate
of 5% has been estimated and the study will require a total of 60 patients (30 patients in
the ORBCEL-C and 30 in the placebo group).
